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Abstract
Alzheimer’s disease (AD) is the most common age-dependent neurodegenerative disease which impairs cognitive
function and gradually causes patients to be unable to lead normal daily lives. While the etiology of AD remains an
enigma, excessive accumulation of β-amyloid peptide (Aβ) is widely believed to induce pathological changes and
cause dementia in brains of AD patients. BACE1 was discovered to initiate the cleavage of amyloid precursor
protein (APP) at the β-secretase site. Only after this cleavage does γ-secretase further cleave the BACE1-cleaved
C-terminal APP fragment to release Aβ. Hence, blocking BACE1 proteolytic activity will suppress Aβ generation.
Due to the linkage of Aβ to the potential cause of AD, extensive discovery and development efforts have been
directed towards potent BACE1 inhibitors for AD therapy. With the recent breakthrough in developing brain-penetrable
BACE1 inhibitors, targeting amyloid deposition-mediated pathology for AD therapy has now become more practical.
This review will summarize various strategies that have successfully led to the discovery of BACE1 drugs, such as MK8931,
AZD-3293, JNJ-54861911, E2609 and CNP520. These drugs are currently in clinical trials and their updated states will be
discussed. With the promise of reducing Aβ generation and deposition with no alarming safety concerns, the amyloid
cascade hypothesis in AD therapy may finally become validated.
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Background
Alzheimer’s disease (AD) is the most common neurode-
generative disorder and is the third leading cause of
death in the elderly behind heart disease and cancer. AD
patients suffer from progressive cognitive decline in the
form of dementia, with memory loss being the earliest
sign. With life expectancy continually increasing, the
number of AD cases is also growing rapidly, and there-
fore treating AD patients is becoming more urgent.
The typical neuropathological hallmarks of AD are the
presence of extracellular amyloid plaques and intracellular
neurofibrillary tangles (NFT), with pathology appearing
initially in the hippocampus and then extending to the
cortical grey matter [5, 64, 69, 83]. Amyloid plaques,
also called senile plaques, result from the deposition of
aggregated Aβ peptides, which can be naturally pro-
duced via sequential cleavages of amyloid precursor
protein (APP) by the β- and γ-secretase [12, 28, 72]. A
membrane-bound aspartyl protease called BACE1 was
discovered as the β-secretase [41, 54, 71, 88, 92], while
the γ-secretase is a complex consisting of four trans-
membrane proteins: presenilin-1 or −2, nicastrin, Aph1,
and Pen2 [11, 20, 52, 53, 100]. Formation of NTF is
due to paired helical filaments of the microtubule-
binding protein tau in hyperphosporylated form [26, 47,
48]. Aβ, mainly Aβ42, appears to induce the formation of
NFT, as implicated by mouse genetic studies [25, 39, 51,
62].
Over the past two decades, extensive knowledge
concerning the molecular mechanisms underlying the
formation of amyloid plaques and NFTs has been
gained. However, the cause of AD still remains largely
under debate. Studies from human genetics and mouse
models indicate that abnormal production or accumula-
tion of Aβ, especially the less soluble form of Aβ (42 or 43
amino acid long Aβ), appears to induce a cascade of
synaptic dysfunctions commonly seen in AD patients
[29, 50, 68, 85, 93]. Hence, targeting Aβ generation or
clearance has been the major focus of research into AD
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therapy [24, 27, 59, 60]. Since BACE1 acts on the first
and rate-limiting step in Aβ generation and BACE1 defi-
ciency almost abolishes Aβ generation in mouse models,
inhibition of BACE1 has received perhaps the most inten-
sive efforts in academia and in industry. With the recent
breakthrough in the development of brain-penetrable
BACE1 inhibitors, several have advanced to clinical trials.
In this review, we will update the progress of these BACE1
inhibitors in human studies.
Discovery of BACE1 inhibitors
For effective and specific inhibition of BACE1, know-
ledge regarding the structure and function of BACE1 is
essential. BACE1 belongs to the family of aspartic prote-
ases, which typically have a bilobal structure, with each
of its two active aspartate motifs [either DTG or DSG]
located in a separate lobe; mutation of either aspartate
residue renders an aspartic protease inactive [79, 82].
Among aspartic proteases, only BACE1 and BACE2 are
localized on the cell membrane via the type I transmem-
brane domain. Although BACE1 and BACE2 share 59 %
homology, they exhibit different enzymatic specificity.
BACE1 mainly cleaves APP at the N-terminus of the
Aβ domain (the β-secretase site) as well as the β’-site
(between E10 and V11), while BACE2 preferentially
cleaves APP within the Aβ region between F19 and F20
or between F20 and A21 [18, 73, 77, 94]. BACE1 defi-
ciency almost abolishes the production of Aβ in mouse
models, while mice deficient in BACE2 show no signifi-
cant difference in Aβ generation [13]. Hence, BACE1 is
viewed as the sole enzyme for initiating Aβ generation.
However, the crystal structure of BACE1, first solved by
the Jordan Tang laboratory, indicates that the proteolytic
site of BACE1 is largely similar to most human aspartic
proteases, although it is more open and less hydrophobic
[33]. These findings suggest potential cross-inhibition of
BACE1 inhibitors, with other crucial aspartic proteases
that are important to normal human functions, will need
to be considered. Among these, cathepsin D and E as well
as BACE2 have received the most attention. Mice deficient
in cathepsin D manifest seizures and become blind near
the terminal stage (postnatal day 26) ([46]. Cathepsin D
knockout mice also develop granular osmiophilic deposits
and abnormal autophagosomes in neonatal neurons [46]
as well as persistent neuropathy related to dysfunctional
lysosomes [70]. Mice deficient in cathepsin E show dis-
rupted immune function due to systemic accumulation
of IL-18 and IL-1β [84] as well as two major lysosomal
membrane sialoglycoproteins, LAMP-1 and LAMP-2
[96]. The mechanism for these defects is mainly through
reduced turnover rates. On the other hand, mice with
BACE2 deficiency have been initially reported to be fertile
and healthy in general [13], suggesting less of a concern
for cross-inhibition. More encouragingly, BACE2 has
been shown to regulate functions of pancreatic β-cells
by shedding the proliferative plasma membrane protein
Tmem27 [8, 16]. In rat pancreatic β- cells engineered
to overexpress islet amyloid polypeptide, BACE2 silencing
can significantly increase glucose-stimulated insulin secre-
tion [2], suggesting a possible beneficial effect for BACE2
inhibition for type 2 diabetic patients. Nevertheless, BACE2
has also been shown to cleave PMEL17 by inhibiting mela-
nosome maturation in melanocytes [67, 86]. Hence, for
cross-inhibition considerations, recombinant cathepsin D,
E and BACE2 should at least be included in in vitro en-
zymatic assay experiments to validate specific effects of
BACE1 inhibitors.
Discovery of BACE1 inhibitors must necessarily in-
clude establishing the physiological functions of BACE1
in human. The generation of BACE1 knockout mice has
been tremendously useful for understanding the role of
BACE1 in vivo. Initial reports of BACE1-null mice sug-
gested that BACE1 deficiency in mice posed no major
concern, as BACE1-null mice appeared to be healthy
[6, 56, 66]. Additional studies with BACE1-null mice,
generated in different laboratories and facilities, have
revealed indispensable roles of BACE1 in vivo such as
the control of myelination [36, 38, 91], neuronal migration
[3, 31, 49, 101], epileptic seizure [32, 40], neurogenesis
and astrogenesis [37], formation of muscle spindle [9], etc.
The development of these phenotypes is due to the
cleavage of additional BACE1 substrates as discussed in
detailed in recent reviews [4, 87, 89, 93, 95]. This know-
ledge is crucial for monitoring mechanism-based toxicity
and for designing clinical trials.
Early stages of BACE1 inhibitors
Immediately after the cloning of BACE1 in the late
1990s, the competition to produce active recombinant
BACE1 enzymes for high-throughput screening (HTS)
of BACE1 inhibitors in many pharmaceutical companies
and academic labs became imminent and intense. The
HTS method has the advantage of generating “small
molecular hits” that often have high structural diversity
and can easily be formulated for oral administration.
Unfortunately, these intense efforts yielded few com-
pounds with in vitro half-maximal inhibitory concentra-
tions (IC50) in the nM range [23, 55]. This can be
attributed to the large BACE1 catalytic pocket, which
has a long substrate cleft and can accommodate a sub-
strate with up to 11 residues [81]. Two noted winners in
the HTS race were Wyeth and Roche. The small BACE1
inhibitory hits at Wyeth have a bicyclic amidine scaffold,
while Roche discovered hits with a dihydrothiazine
scaffold. Both companies further optimized their hits
and developed more potent derivatives in the low μM
range (38–40 μM), which showed reduced cerebrospinal
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fluid (CSF) or cortical Aβ in animal models [30, 57]. In
spite of these initial successes, these BACE1 inhibitors
were not advanced to clinical trials.
In addition to the HTS efforts, other rational designs
of BACE1 inhibitors were simultaneously explored. The
first successful substrate-based BACE1 inhibitor, developed
by Elan Pharmaceuticals, was a P1 (S)-statine-substituted
substrate analogue based on the sequence surrounding the
β-secretase cleavage site (P10–P4′) with an IC50 of ~30 nM
[71]. A more potent hydroxyethylene (HE) isotere-based
transition-state analogue inhibitor, OM99-2, was developed
by the Tang (Oklahoma Medical Research Foundation)
and Ghosh (University of Illinois at Chicago/Purdue
University) team shortly thereafter, with OM99-2 (Glu-Val-
Asn-Leu-Ala-Ala-Glu-Phe) binding to its active site
demonstrated by c-crystallization with BACE1, with a
Ki near 1.0 nM [34]. Hydroxymethylcarbonyl (HMC)
isostere-based transition-state analogs were also developed
and optimized by Kiso’s group (Kyoto Pharmaceutical
University), and eventually pentapeptidic BACE1 inhibi-
tors showed comparable potency with the in vitro IC50 of
KMI-420 being 8.2 nM and that of KMI-429 being 3.9 nM
[44, 45]. Small-molecule hydroxyethylamine dipeptide
isosteres also display high potency of BACE1 inhibition
[74, 80]. Carbinamine-derived BACE1 inhibitors with
the primary amine interacting with the catalytic Asp of
BACE1 were also developed later and showed potency
in the nM range [65]. Although these peptidomimetic
BACE1 inhibitors are highly potent in vitro, their inherent
poor drug properties (i.e., high total polar surface area
with many rotatable bonds and numerous hydrogen bond
donor acceptors) cause poor brain permeability. Peptido-
mimetic BACE1 inhibitors usually have a short half-life in
vivo and low oral availability. This dilemma compels fur-
ther exploration of later generations of smaller, non-
peptidic BACE1 inhibitors in order to improve drug
properties.
The noted successful example of this class is CTS-
21166 from CoMentis [commented by [1]]. CoMentis re-
vealed that CTS-21166 is a small transition-state analog
inhibitor that has an IC50 in the range of 1.2–3.6 nM, has
measurable brain penetration properties, exhibits over
100-fold selectivity over BACE2 and cathepsin D, shows
metabolic stability, and can be orally administered [22].
When an AD mouse model was first tested by intraper-
itoneal (i.p.) injection (4 mg/kg over 6 weeks), CTS-
21166 was shown to reduce brain Aβ levels by over
35 % and plaque load by 40 % [22]. These preclinical
results were clearly encouraging and this compound be-
came the first BACE1 inhibitor to pass a Phase I clinical
trial in 2008. The data based on the CTS-21166 human
Phase I trial in healthy young males indicated that this
compound was safe at dose as high as 225 mg. When
intravenously (i.v.) infused into AD patients, it caused a
dose-dependent reduction of plasma Aβ levels with a
nadir of approximately 80 % inhibition for the highest
dosages at 3 h, and significant inhibition of plasma Aβ
persisted beyond 72 h. The recovery of plasma Aβ to
the pre-infusion level was nearly complete by 144 h
after administration of the inhibitor. A second phase I trial
on subjects receiving an oral liquid solution of 200 mg
CTS-21166 showed similar efficacy [22]. Despite these ini-
tial encouraging results, CTS-21166 has not advanced fur-
ther in clinical trials and the 6-year collaboration between
Astellas Pharma and CoMentis for developing and com-
mercializing CTD-21166 was terminated in 2014. In point
of fact, transition analogs generally possess permeability
glycoprotein efflux activity, which reduces central penetra-
tion/exposure. This class of compounds is therefore less
favorable for central nervous system (CNS) drugs.
Fragment-based discovery improves BACE1
inhibitor pharmacological properties
More successful BACE1 inhibitors have been developed
through “fragment-based drug discovery” (FBDD) [see re-
views by [10, 55, 75, 87]]. Compared to the traditional
HTS approach, the FBDD approach takes advantage of
biophysical techniques (NMR, X-ray co-crystallography,
surface plasmon resonance (SPR), etc.) to screen libraries
that consist of more diverse and smaller-sized compounds
(fragments) for hits. Such hits can be further developed
into potent leads with drug-like properties by medicinal
chemists. A significantly higher hit ratio was obtained
by using a FBDD approach, even though the binding
affinity between the lower-molecular-weight fragments
and the large active site of BACE1 is weaker. Among initial
FBDD screening efforts, hits with amidine- or guanidine-
containing heterocycles were commonly found to form a
hydrogen-bonding network with the catalytic Asp residues
of BACE1 [63]. Overall, the integration of various tech-
niques in the fragment screening has made FBDD an
increasingly popular method for designing potent small-
molecule BACE1 inhibitors. Further optimized compounds
with better CNS drug properties from initial hits are cur-
rently in clinical trials and will be summarized here.
MK-8931 (Verubecestat)
Merck’s BACE1 inhibitor MK-8931 was actually developed
by the BACE1 team at Schering Plough (linked to SCH
900931 in the patent of US 20070287692 A1) through the
FBDD method. In their first FBDD screening and quick
optimization coupled with NMR and a functional assay,
an isothiourea-containing hit with a Kd of 15 μM for
BACE1 was first developed [90]. The H-bond of this hit
interacts with the two catalytic aspartates within the ac-
tive site of BACE1. Additional NMR-based searches for
heterocyclic isothiourea isosteres, optimization of the 2-
aminopyridine, as well as structure-based design of a cyclic
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acylguanidine led to BACE1 inhibitors with nanomolar Kd
as well as better chemical stability and physicochemical
properties [102]. Optimization of the pyrimidine substitu-
ent that binds in the S2′-S2″ pocket of BACE1 remediated
time-dependent CYP3A4 inhibition of earlier analogues in
this series and imparted high BACE1 affinity [58]. This
compound, named MK-8931 or Verubecestat, has the for-
mula of C17 H17 F2 N5 O3 S (see Fig. 1), and effectively re-
duces Aβ40 in cells with a Ki of 7.8 nM and an IC50 of 13
nM [76]. It also dramatically lowered CSF and cortex Aβ40
in both rats and cynomolgus monkeys following a single
oral dose [58].
In 2010, MK-8931 was the first small molecular
BACE1 inhibitor to enter a clinical phase I trial, with an
initial evaluation in 88 people (40 for single doses of 100
or 450 mg in Belgium and 48 for multiple escalating
doses of 12–150 mg in the USA). Another trial was tar-
geted to people with renal insufficiency in order to assess
efficient clearance of the drug. MK-8931 was presented as
having excellent safety profiles with no immediately notice-
able side effects. A single dose of MK-8931 reduces CSF
Aβ concentrations in AD patients by as much as 92 %,
while multiple low doses achieve a reduction of 50–80 %
[19].
In Phase 1b randomized placebo-controlled trials, 32 in-
dividual with mild to moderate AD received 12 mg,
40 mg, and 60 mg of MK-8931 once daily for 7 days.
Aβ40, Aβ42, and BACE1-cleaved secreted amyloid precur-
sor protein β (sAPPβ) in CSF were collected and analyzed.
Merck reported a dose-dependent and sustained reduc-
tion from baseline by 57, 79, and 84 % for CSF Aβ40 with
these three dosages (http://www.mercknewsroom.com/
press-release/alzheimers-disease/merck-presents-findings-
phase-1b-study-investigational-bace-inhibit). Reductions
in Aβ42 and sAPPβ were of a similar range. The results
concerning safety, tolerability, pharmacokinetics, and phar-
macodynamic profile support MK-8931 for testing at the
next level.
In late 2012, Merck promptly launched combined Phase
II/III clinical trials. This global EPOCH study would enroll
1960 individuals and is designed in two parts, Part I and
Part II. Part I of the study is designed to assess the efficacy
and safety of verubecestat (MK-8931) compared with pla-
cebo administered for 78 to 104 weeks for the treatment
of AD patients with amnestic mild cognitive impairment,
also known as prodromal AD. Participants randomized to
receive one dose (12 or 40 mg verubecestat, once daily)
will be compared with a placebo group for changes from
Fig. 1 Chemical structure of compound MK-8931. MK-8931 is developed at Merck and also named as Verubecestat with a Chemical formula of
C17 H17 F2 N5 O3 S. It’s structural name is N-[3-[(5R)-3-amino-5,6-dihydro-2,5-dimethyl-1,1-dioxido-2H-1,2,4-thiadiazin-5-yl]-4-fluorophenyl]-5-fluoro-
2-pyridinecarboxamide. The molecular weight is 409.41
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baseline in the Clinical Dementia Rating scale-Sum of
Boxes (CDR-SB) score at 78 or 104 weeks. Participants
entering Part II will receive either 12 mg or 40 mg verube-
cestat, once daily for up to an additional 260 weeks. This
combined trial will assess changes from baseline in cogni-
tion and function using several tests, but will also assess
AD biomarkers, such as CSF total tau, hippocampal
volume, and brain amyloid (Table 1). It is expected that
Merck will report results from this study between 2018
and 2021.
AZD-3839 and AZD-3293
AstraZeneca is another leading pharmaceutical company
engaged in the identification of 6-substituted isocytosine
as a novel compound against BACE1 through fragment-
based 1D NMR screen together with characterization by
BIAcore and co-crystalization [21]. This initial fragment
hit with an isocytosine core has mM potency. By NMR
affinity screening and structure-guided evolution, to-
gether with X-ray crystallography and potency deter-
mination using surface plasmon resonance, a series of
compounds with the dihydroisocytosine scaffold were
found to be more potent through functional enzyme in-
hibition assays [14]. The most potent compound in this
series has an IC50 of 80 nM for BACE1 inhibition. Using a
scaffold hopping protocol from dihydroisocytosine to ami-
nohydantoin, the potent compound AZD-3839 (Fig. 2a),
with an IC50 of 4.8 nM for Aβ40 reduction and an IC50 of
16.7 nM for sAPPβ reduction, was finally developed [78].
AZD-3839 has 14 and >1000-fold greater selectivity over
BACE2 and cathepsin D, respectively, and orally adminis-
trated AZD-3839 shows dose- and time-dependent lower-
ing of plasma, brain, and CSF Aβ40, Aβ42, and sAPPβ
levels in mouse (C57BL/6 WT mice), guinea pig, and non-
human primate [42]. Interestingly, treatment with this
compound showed a biphasic effect, which causes an ini-
tial small increase in Aβ levels followed by a subsequent
significant reduction in Aβ, similar to our previous reports
for γ-secretase inhibition [7]. It has also been reported
that the IC50 values to reduce Aβ40 in plasma were 64-
and 48-fold lower than those in brains for mouse and
guinea pig, respectively [42]. Based on the overall pharma-
cological profile and its drug-like properties shown in ani-
mal studies, AZD-3839 was advanced to Phase 1 clinical
trials in May 2011 in the UK, but these were terminated
in December, 2012. It is not known whether this was
related to the high affinity of AZD-3839 for the human
ether-a-go-go related gene (hERG) ion channel as pre-
viously reported [78].
Despite this setback, AstraZeneca launched multiple
phase I trials on another compound AZD-3293 (see struc-
ture in Fig. 2b) in December, 2012. AZD-3293 was licensed
from Astex Pharmaceuticals as a potent BACE1 inhibitor
with a [Ki] of 0.4 nM by an enzymatic TR-FRET assay [15].
In this report, it showed inhibition of Aβ40 and sAPPβ in
the pM range in SH-SY5Y cells over-expressing AβPP
(IC50 = 610, 310, and 80 pM, respectively), and showed
nearly equal potency against BACE2 but a >25,000-
and >41,000-fold selectivity against cathepsin D and γ-
secretase cleavage of Notch IC50 values, respectively.
The IC50 for brain Aβ40 reduction was estimated to be
600 pM in mice, 900 pmol/L (CV 4 %) in guinea pigs,
and 800 pmol/L (CV 9 %) in dog. Based on free AZD-
3293 concentration in the CSF, the IC50 for Aβ40 reduc-
tion is 3.8 nmol/L (CV 31 %). The affinity of AZD-3293
on hERG was also investigated by the whole-cell patch
clamp technique using hERG-expressing CHO cells and
the IC50 for the inhibition of hERG is over 33 μM.
The encouraging results in animals are apparently
correlated with human studies. In the 2014 13th Inter-
national Geneva/Springfield Symposium on Advances
in Alzheimer Therapy, AstraZeneca reported successful
phase I trial results from 72 healthy volunteers, which
showed a reduction of CSF Aβ as much as 75 % that re-
quires 2 to 3 weeks after treatment to return to baseline
levels (http://www.alzforum.org/news/research-news/bace-
inhibitor-heads-phase-23-trials).
In September 2014, AstraZeneca and Eli Lilly an-
nounced joint development of AZD-3293 and the imple-
mentation of a pivotal Phase II/III trial enrolling 2202
patients selected by multiple NIA-AA criteria for MCI
due to AD or mild AD and confirmed by either an amyloid
PET scan or a lumbar puncture (http://www.alzforum.org/
therapeutics/azd3293). This 5-year trial will compare two
doses given once daily as a tablet to placebo and will
measure success by changes from baseline on the clin-
ical dementia rating sum of boxes (CDR-SOB) (Table 1).
The ADAS-cog and ADCS-ADL are secondary out-
come measures, along with other clinical markers as
well as change in CSF markers, functional and amyloid
PET, and MRI.
To test potential interactions of AZD-3293 with
commonly prescribed drugs such as the blood thinners
warfarin and dabigatran, the sedative midalozam, a lipid-
lowering medication simvastatin (Zocor) as well as inhibitor
of cholinesterases donepezil (Aricept), AstraZeneca ad-
ded three additional phase I trials in a total of 157
healthy volunteers in 2015. No results have been report
thus far.
JNJ-54861911
In March 2013, Janssen began Phase I trials of JNJ-
54861911, which was initially developed by and li-
censed from Shionogi & Co. in Japan and developed
through the collaboration between two companies. JNJ-
54861911 was optimized through multiple steps by the
Shionogi group from hits with amino-dihydrothiazine
or modified versions of the cyclic isothiourea warhead
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Table 1 BACE1 inhibitors in clinical trials
Drug MK-8931 JNJ-54861911 AZD-3293 E2609 CNP520
Sponsor Merck Janssen, Shionogi Pharma AstraZeneca, Eli Lilly Eisai, Biogen Novartis, Amgen
Trial # (Phase) NCT01739348 (II/III) NCT02406027 (II) NCT02245737 (II/III) NCT02322021 (II) NCT02576639 (II)
NCT01953601 (II/III) NCT02406027 (II) NCT02565511 (II/III)
NCT02569398 (II/III)
Dose 12, 40 or 60 mg 10, 25 or 50 mg 20 or 50 mg 25, 50, 100 and 200 mg 1, 10, 25 and 75 mg
Trial duration 78, 104 and 260 weeks 26, 52 or 96 weeks or 54 months 97 or 104 weeks 18 months 13 weeks and 5 years
1st Outcomes Baseline change in ADAS-Cog
and ADCS-ADL scores
Safety measure by AEs or SAEs
up to 10 months; Baseline change
in ADCS-PACC Score (54 weeks),
Baseline change in CDR-SB Score Baseline change in ADCOMS,
Safety measure by AEs or SAEs
Safety measure by AEs or SAEs
2nd Outcomes Baseline change in CDR-SB
score; CSF tau, brain amyloid load,
NPI score, hippocampal volume,
MMSE, score, etc.
Baseline change in CSF and plasma
Aβ37, Aβ38, Aβ40, Aβ42, sAPPα, sAPPβ,
Tau; CFI; CDR-SB, Neurodegeneration
by Assessing Changes in Imaging
Biomarkers, etc.
Baseline change in ADAS-Cog-13
score; CSF Aβ40, Aβ42, Tau; brain
amyloid load by PET imaging, while




change in CSF and plasma
Aβ1-x, etc.
Baseline change in CDR-SB score;
CSF Aβ40, Aβ42, total tau and
phosphorylated tau, volumetric
MRI; Everyday Cognition scale, etc.
More detailed measures of outcomes are listed under each trail protocol in the relevant website
Abbreviations used in the table: ADAS-Cog-13 Score Alzheimer’s disease assessment scale- cognitive subscale score, ADCOMS Alzheimer’s disease composite score, ADCS-ADL Alzheimer’s disease cooperative study
activities of daily living inventory instrumental items score, ADCS-PACC Score Alzheimer’s disease cooperative study preclinical alzheimer cognitive composite score, CDR Score change in clinical Dementia rating global
score, CDR-SB Score the clinical Dementia rating - sum of boxes score, CFI cognitive function index, FAQ Score functional activities questionnaire score, MMSE Score mini-mental state examination score, NPI Score









[63]. By the cyclopropane-based conformational restric-
tion approach, replacing an amidine group with chiral
cyclopropane rings, or adding an amide linker between
the two aryl rings as exemplified, multiple compound
series were explored [97–99]. These efforts eventually
yielded more potent and bioavailable JNJ-54861911
(structures have not been revealed yet). Phase I trial par-
ticipants were given various doses (1, 3, 9, 27, 81, and
160 mg in healthy volunteers or 5, 10, 25, and 90 mg in
elderly volunteers) of JNJ-54861911 or placebo once daily
for 14 days to 4 weeks. In an AD/PD conference held in
Nice in 2015, Dr. Johannes Streffer from Janssen reported
that those taking the drug showed safe profiles in 94
people. The compound crossed the blood-brain barrier
and displayed dose-dependent reduction of all four
forms of Aβ peptides (Aβ37, Aβ38, Aβ40, and Aβ42). A
dose of 25 mg showed reduction of CSF Aβ concentra-
tions by 80 %, and up to 95 % Aβ reduction was
achieved with once-daily oral dosing of 90 mg. Reduc-
tion of the BACE cleavage product sAPPβ correlated
with reduction of Aβ, whereas levels of sAPPα rose by 2-
to 2.5-fold, a method first reported for assessing BACE1
activity [92].
In October 2015, a phase IIb/III randomized, double-
blind, Placebo-Controlled trial were launched in Europe,
Australia, and Mexico. The study is expected to enroll
1650 individuals who are asymptomatic but at risk for
developing Alzheimer’s dementia (Table 1). The trial will
investigate the efficacy and safety of JNJ-54861911. A
dose of either 10 or 25 mg of drug will be given for
54 months for end-point evaluation. In January, 2016,
Janssen added a phase I study in 32 healthy adults in
Germany to evaluate drug interactions between JNJ-
54861911 and the anti-diabetic metformin or rosuvasta-
tin (also called Crestor for cholesterol reduction).
E2609
Although not explicitly described, Eisai may have also
identified its potent BACE1 inhibitor E2609 through
FDBB screening. In his review, Oehlrich implied that
Eisai developed its BACE1 inhibitor through several
series of bicyclic aminodihydrothiazines fused with un-
saturated five- and six-membered rings, eventually cul-
minating in a structure similar to a Merck BACE1
inhibitor, with a Ki of 27 nM [63]. Significant reduc-
tions in Aβ levels in the CSF and plasma in nonhuman
primates were demonstrated in preclinical animal testing
(poster presentation by Fukushima T, Lucas F at the 2012
Alzheimer’s Association International Conference). In two
standard phase I trials, 73 healthy adult individuals
received single doses of E2609 between 5 and 800 mg
(divided into nine cohorts), while another 50 individ-
uals received E2609 doses between 25 and 400 mg
daily for 14 days. The drug E2609 showed tolerability
at all doses tested for single use, with the most com-
mon adverse events included headache and dizziness.
Individuals receiving repeated doses up to 200 mg had
no clinically significant safety concerns. In both cases,
plasma Aβ [Aβ(1-x)] levels were measured prior to pa-
tients receiving E2609. The maximum dose-dependent
reduction of plasma Aβ(1-X) relative to baseline was
52 % at 5 mg and 92 % at 800 mg. The percentage de-
crease in CSF Aβ(1-x) after 14 days dosing compared
to baseline was statistically significant, showing a 46.2,
61.9, 73.8, and 79.9 % reduction compared to placebo
in the 25, 50, 100, and 200 mg cohorts, respectively. In
November, 2014, these encouraging results led Eisai to
announce a large phase II dose-finding study by collab-
orating with Biogen. It will enroll 700 people with MCI
due to AD or prodromal AD and being amyloid PET-
scan positive.
Fig. 2 Chemical structures of compound AZD-3293. a AZD-3289 is a potent BACE1 inhibitor with a chemical formula of C26H28N4O and a structure name
of (3S)-3-[2-(difluoromethyl)pyridin-4-yl]-7-fluoro-3-(3-pyrimidin-5-ylphenyl)-1,2-dihydroisoindol-1-amine. It’s molecular weight is 449. b AZD-3293 is
developed at AstraZeneca and Astex with a chemical formula of C26H28N4O and structural name of 4-Methoxy-5′′-methyl-6′-[5-(prop-1-yn-1-yl)pyridin-3-
yl]-3′H-dispiro[cyclohexane-1,2′-indene-1′,2′′-imidazole]-4′′-amine. It’s molecular weight is 412. 54
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CNP520
In late 2015, Novartis announced a global collaboration
with Amgen to test a BACE inhibitor, CNP520, in hu-
man trials and to develop further compounds from the
pre-clinical BACE inhibitor programs of both companies.
Novartis’ CNP520 is formulated to be taken as capsules
for oral administration and has gone through preclinical
studies in the company, although little information on the
potency and structure of this drug has been disclosed. It is
expected to have efficacy high enough for moving the
compound into multi-site phase I/IIa trials in the
Netherlands, Belgium, Germany, the UK, and the USA
(http://www.alzforum.org/therapeutics/cnp520). Doses of
CNP520 ranging from 1, 10, 25, and 75 mg will be given
to 125 healthy individuals between 60 and 80 years of age
once daily for 13 weeks and Aβ38, 40, and 42 will be mea-
sured at the end of trials for comparison to baseline levels.
The unique part of Norvatis’ Phase II/III trial, an-
nounced in November, 2015, is to test two investigational
drugs, CNP520 and CAD106. CAD106 was developed at
Novartis for active vaccination using multiple copies of
Aβ1-6 peptide derived from the N-terminal B cell epitope
of Aβ (http://www.alzforum.org/therapeutics/cad106). Five
phase II trials involving a total of 274 people were con-
cluded in 2014, and no major safety concerns in individuals
administrated CAD106 for 55 to 66 weeks were reported,
while induction of Aβ-specific antibody was evident [17].
In combining with this Aβ-clearance strategy, administra-
tion of CNP520, administered separately, is expected to
stop generation of Aβ and to remove existing Aβ plaques.
This combination of trials will enroll 1340 homozygous
ApoE4 carriers between the ages of 60 and 75. In this 5-
year trial, about half of the participants will be injected
with CAD106 intramuscularly at weeks 1, 7, 13, 24 and
then quarterly randomized to compare to matching place-
bos. The other half will be randomized to compare once-
daily CNP520 to matching placebos. The trial results will
not likely be released until 2023.
Norvatis also developed another compound named NB-
360, which shows potent inhibition of BACE1 in APP
transgenic mice, rat and pigs [61], but this compound has
not yet been developed for clinical trial.
Conclusions
Over the past decade, substantial research efforts have
been directed toward understanding BACE1 as a critical
target for AD therapy. Although FBDD-based hits have
been successful in advancing BACE1 inhibitors to clinical
trials, discovery of BACE1 inhibitors by HTS or in silico
designs should not be discounted, as they also yielded hits
that were further optimized to increase potency at Wyeth
and Roche. For example, HTS identified amidine-based
pharmacophore, which was independently discovered
by FBDD, showing an important convergence in drug
discovery.
While there is clear evidence that brain-penetrable
BACE1 inhibitors reduce Aβ generation and likely amyl-
oid deposition, the safety profiles for long-term use of
these inhibitors should be closely monitored. Studies
based on the characterizations of BACE1-null mice have
revealed roles of BACE1 in myelination, ion channel activ-
ities, neuronal migration and excitation, and astrogenesis
[see recent reviews by [4, 35, 43, 89, 95]]. In addition to
potential on-site toxicity, many promising drugs are
doomed by having certain off-site toxicity, and any in-
tolerable toxicity will prevent the further application of
some drugs in humans. Safety fears have prompted termin-
ation of several BACE1 inhibitors in trials. LY-2811376 and
LY-2886721 from Eli Lilly, AZD-3839 from AstraZeneca,
and RG-7129 from Roche were all terminated during
clinical trials. While both compounds from Eli Lilly
were reported to cause unacceptable side effects (due
to evidence of liver toxicity in patients), the reasons for
the termination of the trials involving the latter two
drugs were not disclosed. Another orally active BACE1
inhibitor, BI1181181/VTP-37948, discovered by Vitae
Pharmaceutics and developed by Boehringer Ingelheim,
finished two Phase 1 clinical trials and demonstrated
strong potency in reducing brain Aβ in volunteers in
October of 2014. Surprisingly, this compound was not
advanced to further clinical trials by these two ventured
companies. In fact, Boehringer has terminated develop-
ment of BI1181181 in July 2015, likely related to con-
cerns regarding side effects of this experimental BACE1
inhibitor drug. Hence, placing safe BACE1 inhibitory
drugs on the market remains challenging, despite the
great promise shown in several trials.
Despite the above concerns and challenges, it should
be recognized that BACE1 is perhaps the best target for
reducing Aβ generation, considering the relatively mild
phenotypes exhibited by BACE1-null mice. This may be
related to the fact that most BACE1 substrates can also
be complementarily processed by α-secretase for ectodo-
main shedding. Indeed, after the initial reports of the
BACE1 sequence in late 1999, drug discovery efforts in
blocking BACE1 activity in humans have never been
abandoned, no matter how many challenges were pre-
sented over the past 17 years. There is great anticipation
that optimal inhibition of BACE1 in humans will eventu-
ally answer whether a so-called “amyloid hypothesis”-
based strategy is the best way to improve cognitive function
in AD patients.
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